Commenting on the study for Psychiatric News, Alice Flaherty, M.D., Ph.D., an assistant professor of neurology at Harvard Medical School and the Movement Disorders Fellowship
director at Massachusetts General Hospital, said the results are encouraging, "[But] doctors and patients should be aware
that commercially available ginkgo pills are often sold by gram of herb, and the percentage of ginkgo biloba extract can vary
dramatically. [Also] the average AIMS scores of the patients were not dramatic. The group average at start was 7 out of a
maximum of 42, and on average their scores fell only 2 points. [Thus] the drug might make a cosmetic improvement, but few
if any patients had complete removal of their symptoms."